
    
      Up to 462 patients 18 years of age and older, with confirmed clinical diagnosis of rosacea
      will be enrolled to have 413 in the modified intent-to-treat (mITT) population and 371 in the
      per-protocol (PP) population. Patients should have fewer than 3 facial inflammatory lesions,
      and moderate to severe erythema according to both Clinician's Erythema Assessment (CEA) and
      Patient's Self-Assessment (PSA).
    
  